"10.1371_journal.pbio.1002344","plos biology","2016-01-06T00:00:00Z","Rob N de Jong; Frank J Beurskens; Sandra Verploegen; Kristin Strumane; Muriel D van Kampen; Marleen Voorhorst; Wendy Horstman; Patrick J Engelberts; Simone C Oostindie; Guanbo Wang; Albert J R Heck; Janine Schuurman; Paul W H I Parren","Genmab, Utrecht, The Netherlands; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; Netherlands Proteomics Centre, Utrecht, The Netherlands; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark; Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands","Conceived and designed the experiments: RNdJ FJB SV MDvK GW AJRH JS PWHIP. Performed the experiments: RNdJ MV WH PJE SCO GW. Analyzed the data: RNdJ FJB SV MDvK MV WH PJE SCO GW AJRH JS PWHIP. Wrote the paper: RNdJ FJB SV KS AJRH JS PWHIP.","I have read the journals policy and the authors of this manuscript have the following competing interests: RNdJ, FJB, SV, KS, MV, WH, PJE, SCO, MDvK, JS and PWHIP are Genmab employees and own Genmab warrants and/or stock. RNdJ, FJB, JS and PWHIP are inventors on Genmab patent applications. In this manuscript we described the identification of a new antibody platform for the development of therapeutic antibodies, which we have registered under the trade name HexaBody.","2016","01","Rob N de Jong","RNDJ",13,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
